Partners & Investors
Value Proposition: Oligomerix is a highly differentiated biopharmaceutical company targeting tau oligomers for treatment and diagnosis of Alzheimer’s disease and other neurodegenerative disorders. It has developed two highly differentiated drug discovery programs: small molecules oligomer inhibitors and tau protease inhibitors. Each approach has its own associated biomarkers programs. These are enabling and accelerating technologies for large pharmaceutical licensees, partners and acquirers that will play a major role in successfully intervening in this costly, debilitating disease.